Shuanglu Pharmaceutical Co., Ltd.
SZSE · 002038
Market Cap$5.8B
Revenue$591.6M
Employees901
Listed OnSZSE
Ticker002038
IndustryDrug Manufacturers - Specialty & Generic
CEO / ExecDr. Mingbo Xu Ph.D.
HeadquartersBeijing
MarketMainland China
Websitewww.slpharm.com.cn
Overview
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; pegylated human granulocyte-stimulating factor injection; human granulocyte-cell stimulating factor injection; recombinant human basic fibroblast growth factor for external use recombinant human basic fibrobl
Data Note
This record combines exchange-directory fields with selected profile enrichment. Treat market data, leadership and financial figures as directional unless verified against company filings, exchange announcements or the issuer's own disclosures.